William Blair says the Wall Street Journal article on safety concerns around Zoetis’ Librela and Solensia drugs for dog and cast osteoarthritis pain does not introduce new information into the ongoing safety debate. The article highlights a couple of anecdotal cases where pets experienced serious adverse events and includes additional context with veterinary quotes on the products, the analyst tells investors in a research note. The firm acknowledges headline risk from the story but says its talks with management support a bullish view on Librela. Blair maintains an Outperform rating on Zoetis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
- Zoetis price target lowered to $195 from $215 at Stifel
- Zoetis Expands Board with New Director, Emphasizes Governance
- 5 Best Healthcare Stocks to Buy in March 2024, According to Analysts
- Discounted Zoetis price offers buing opportunity, says Argus